Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track ANRO with free AI briefings, catalyst countdowns, and dilution alerts.

ANRO · Alto Neuroscience, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$319.3M Cash on Hand
47.3mo Cash Runway
16.6% Short Interest
$38.67 Analyst Target (9)
Follow ANRO by email Get an email when ANRO reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about ANRO, unsubscribe in one click. Privacy

📣 What ANRO Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Bupropion Major Depressive Disorder Phase 4 · NCT04388189 Withdrawn
ALTO-100 Bipolar Disorder I or II With a Major Depressive Episode Phase 2 · NCT06656416 Recruiting
ALTO-100 PO Tablet Major Depressive Disorder Phase 2 · NCT05419869 Completed
ALTO-101 Schizophrenia Phase 2 · NCT06502964 Recruiting
ALTO-203 25 μg Major Depressive Disorder Phase 2 · NCT06391593 Completed
ALTO-203 75 μg Major Depressive Disorder Phase 2 · NCT06391593 Completed
ALTO-207 Treatment-resistant Depression (TRD) Phase 2 · NCT07553637 Recruiting
ALTO-300 Major Depressive Disorder Phase 2 · NCT05922878 Recruiting
ALTO-300 PO Tablet Major Depressive Disorder Phase 2 · NCT05157945 Completed

Also used in these trials (approved or third-party drugs, not ANRO's own candidates): Duloxetine, Escitalopram Oral, Sertraline.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

ANRO holds $319.3M in cash and short-term investments (as of Sep 30, 2026) and burns about $20.3M/quarter from operations, an estimated runway of 47.3 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 39 · Moderate

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when ANRO files for a raise →

👥 Who Owns ANRO

Insiders 2.4% Institutions (181 holders) 94.7% Public and other holders 2.9%
HolderTypeShares% of sharesAs of
Perceptive Advisors LLC Institution (13G, 5%+) 4,176,711 10.41% 2026-06-30
Alpha Wave Global, LP Institution (13F) 3,707,757 9.24% 2026-09-30
Commodore Capital LP Institution (13G, 5%+) 3,588,180 8.95% 2026-03-31
EcoR1 Capital, LLC Institution (13G, 5%+) 2,232,000 5.56% 2026-07-13
Sirenia Capital Management LP Institution (13G, 5%+) 2,219,568 5.53% 2026-06-30
BlackRock, Inc. Institution (13G, 5%+) 2,104,406 5.25% 2026-06-30
Vanguard Capital Management Institution (13G, 5%+) 1,970,108 4.91% 2026-09-30
Adage Capital Partners GP L.L.C. Institution (13F) 1,701,913 4.24% 2026-09-30
Spruce Street Capital LP Institution (13F) 1,676,558 4.18% 2026-09-30
Vivo Capital, LLC Institution (13F) 1,359,915 3.39% 2026-09-30
Price (T.Rowe) Associates Inc Institution (13F) 1,283,867 3.20% 2026-09-30
Franklin Resources, Inc. Institution (13F) 993,485 2.48% 2026-09-30

Share count 40,110,620 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-09-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.

📈 Recent Insider Activity (Form 4)

Trade dateInsiderTransactionSharesPriceOwned after
2026-10-02
filed 2026-10-05
Smith Nicholas Conrad
Option exercise (M) 55,000 $2.32 79,060
2026-10-02
filed 2026-10-05
Smith Nicholas Conrad
Option exercise (M) 55,000 – –
2026-09-30
filed 2026-10-01
Smith Nicholas Conrad
Option exercise (M) 24,056 $2.35 48,116
2026-09-30
filed 2026-10-01
Smith Nicholas Conrad
Sale (S) 23,170 $25.78 24,946
2026-09-30
filed 2026-10-01
Smith Nicholas Conrad
Sale (S) 886 $26.87 24,060

Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.

Get the full ANRO picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ANRO and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.